Published in Vaccine Weekly, November 6th, 2002
The two contracts total $22.5 million through FY 2003.
"There is an urgent need to devise more effective measures to protect U.S. citizens from the harmful effects of anthrax spores used as instruments of terror," said Thompson. "These awards represent the first step toward our goal of securing an initial 25 million doses of an improved anthrax vaccine for our emergency stockpile."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.